🌅 Today's Morning Call
|
S&P Futures
6,452.25
▲ +8.25 (+0.13%)
|
Nasdaq Futures
23,357.00
▲ +36.75 (+0.16%)
|
Dow Futures
45,943.00
▲ +70.00 (+0.15%)
|
|
10Y Treasury
4.34%
▼ -0.10%
|
US Dollar
100.30
▼ -0.15 (-0.15%)
|
Bitcoin
$66,699
▲ +$7 (+0.01%)
|
Data as of 8:08 AM ET
Good morning! Futures are edging higher to close out the quarter, with the S&P 500 up 8 points and the Nasdaq gaining 37 in early trading. Big pharma is making waves with over $12 billion in M&A action, while Microsoft faces regulatory headwinds across the pond. Treasury yields are pulling back and the dollar is slipping as markets digest a mixed bag of corporate news to end March. Here's your morning rundown.
👀 What to Watch Today
The final trading day of Q1 2026 brings plenty of crosscurrents to navigate. All eyes are on how the major indexes close out what's been a volatile March, particularly with Treasury yields dipping across the curve and the Dollar Index sliding to 100.30.Pharma M&A is dominating the pre-market conversation. Biogen (BIIB) is shelling out $5.6 billion for Apellis Pharmaceuticals (APLS), while Eli Lilly (LLY) is going even bigger with a $6.3 billion acquisition of Centessa Pharmaceuticals (CNTA) to boost its sleep disorder treatment pipeline. These mega-deals signal continued consolidation in the healthcare space.
On the regulatory front, Microsoft (MSFT) faces fresh scrutiny as UK antitrust authorities announced plans to launch an investigation into its business software licensing practices starting in May. Add to that the company's $1 billion Thailand investment for cloud and AI infrastructure, and MSFT has plenty of moving parts today.
🌏 Overnight Recap
Asian markets traded mixed overnight as investors digested the same pharma deal flow that's lifting U.S. futures. The EU energy chief issued a stark warning about long-term energy market disruption stemming from the Iran conflict, a cautionary note that's keeping a floor under oil prices despite broader risk-on sentiment.Gold continues its historic slide, on track for its worst monthly decline since 2008 with a stunning 14.6% drop in March. Safe haven demand has evaporated as the Iran situation evolves, and spot prices are struggling to find footing even as Treasury yields retreat. The gold-linked ETFs (AAAU, BAR, DBP) are feeling the pain.
European markets are trading modestly higher, shrugging off the energy disruption warnings for now. The dollar's weakness is providing some support to international equities, though the energy sector remains on edge about supply chain implications from Middle East tensions.
Sponsored Content
Trump's Next Export Ban Could Reshape the Global Economy
It's not semiconductors, AI chips or quantum computers. But none of those technologies can exist without it. On July 1st, 2026, Trump is expected to ban exports of something every tech company desperately needs—forcing them all to relocate to U.S. soil.
📊 Pre-Market Movers
Apellis Pharmaceuticals (APLS) and Centessa Pharmaceuticals (CNTA) are the obvious standouts, getting bought out at substantial premiums. APLS fetches $5.6 billion from Biogen, while CNTA is going to Eli Lilly for $6.3 billion. Shareholders in both targets should see significant pops at the open.Novo Nordisk (NVO) is generating buzz with its new discounted subscription plan for Wegovy, offering up to 30% savings for U.S. self-pay patients. The move could expand market access and boost volume, though it signals pricing pressure in the competitive GLP-1 weight loss space.
Delta Air Lines (DAL) and Amazon (AMZN) announced a partnership for in-flight Wi-Fi starting in 2028, with Amazon's Leo satellite service joining the connectivity race against Starlink. Polestar (PSNY) is moving after Volvo (VLVCY, VLVLY) doubled its stake to nearly 20% through a debt-to-equity swap, providing financial breathing room for the struggling EV maker.
🔍 Today's Watchlist
- Healthcare M&A: BIIB/APLS and LLY/CNTA deals totaling $12B
- Microsoft regulatory pressure in UK, $1B Thailand investment
- Gold ETFs (AAAU, BAR, DBP) facing worst month since 2008
- EU energy disruption warnings from Iran conflict escalation
- Quarter-end positioning flows and Treasury yield pullback
Sponsored Content
Is Silver's Historical Run Just Getting Started?
Silver is no longer playing second fiddle to gold. After 2025's historic 150% surge, silver keeps charging higher. There's a massive global supply deficit, widespread global uncertainty, and an insatiable demand fueled by A.I. and green energy. With analysts forecasting an imminent move toward triple digits, the cost of waiting has never been higher.
🎯 The Morning Playbook
The pharma consolidation wave tells you everything about where big money sees value right now. When Biogen and Eli Lilly are writing multi-billion dollar checks for pipeline assets, it signals confidence in pricing power and long-term demand despite regulatory scrutiny. Watch how these deals get received, it could spark more M&A activity.Microsoft's dual narrative, regulatory pressure in the UK but continued international expansion in Thailand, captures the challenge for mega-cap tech in 2026. Growth opportunities exist, but the regulatory moat is tightening. Position accordingly.
As we close the books on Q1, remember that quarter-end can bring unusual flows and volatility. Don't read too much into today's price action alone. Focus on the bigger themes: pharma consolidation, tech regulation, persistent energy concerns, and gold's stunning reversal. The trends matter more than the tape today.